BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMA Biologics (ADMA)ADMA BiologicsEarnings

1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7 Million, 22% Year-Over-Year Growth 1Q 2026 Adjusted EBITDA ( 2) of $59.7 Million, Representing 24% Year-Over-Year

Open original release

Related news

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

ADMAADMA Biologics2026-02-25 21:05 EST

ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

RXRXRecursion2026-05-06 10:30 EST

Recursion Reports First Quarter Financial Results and Provides Business Update

MDXGMiMedx2026-04-29 20:01 EST

MIMEDX Announces First Quarter 2026 Operating & Financial Results

RXRXRecursion2026-04-29 11:59 EST

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

MDXGMiMedx2026-04-22 12:00 EST

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

CHRSCoherus BioSciences, Inc.2026-03-09 20:15 EST

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

IBIOIbio Inc2026-05-12 20:05 EST

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

IBIOIbio Inc2026-02-10 21:05 EST

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

View all latest news

ADMA Biologics

ADMA Biologics is a plasma-derived biologics company focused on immunoglobulin therapies and specialty immune products. Its business is centered on plasma supply, manufacturing, and commercial execution.

Recent company news

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

ADMAADMA Biologics2026-03-27 11:00 EST

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

ADMAADMA Biologics2026-03-25 10:30 EST

ADMA Biologics Addresses Misleading Short-Seller Report

Stock data

Close
8.48 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States